Phase 2 Fabry Disease Clinical Trial Has Been Stopped Due to Negative Outcomes
source: pixabay.com

Phase 2 Fabry Disease Clinical Trial Has Been Stopped Due to Negative Outcomes

Avrobio has just announced that they will be stopping work on their investigative gene therapy for Fabry disease based on unexpected and disappointing results from a Phase 2 clinical trial.…

Continue Reading Phase 2 Fabry Disease Clinical Trial Has Been Stopped Due to Negative Outcomes
The Brighter Days Care Package Program for Cystinosis Patients and Families has Launched
source: pixabay.com

The Brighter Days Care Package Program for Cystinosis Patients and Families has Launched

The Cystinosis Research Network (CRN) has created a new program to bring light to cystinosis families during these uncertain times. It is called the Brighter Days Care Package Program. Brighter…

Continue Reading The Brighter Days Care Package Program for Cystinosis Patients and Families has Launched
Early Success in Trials for Experimental Gene Therapies for Fabry Disease and Cystinosis
source: pixabay.com

Early Success in Trials for Experimental Gene Therapies for Fabry Disease and Cystinosis

As reported in Business Fortnight, the top level gene therapy company AVROBIO has announced successful clinical trials for investigational drugs for Fabry disease and cystinosis. The CEO of AVROBIO, Geoff…

Continue Reading Early Success in Trials for Experimental Gene Therapies for Fabry Disease and Cystinosis
Study Examines Neurological Differences in Cystinosis Patients
source: pixabay.com

Study Examines Neurological Differences in Cystinosis Patients

In a study published recently in the Orphanet Journal of Rare Diseases, a team of researchers identified distinct variations in the neuroanatomical and neuropsychiatric phenotypes of cystinosis patients. Phenotype refers to visible,…

Continue Reading Study Examines Neurological Differences in Cystinosis Patients
First Patient Dosed in Phase I/II Study of Experimental Gene Therapy for Cystinosis
source: pixabay.com

First Patient Dosed in Phase I/II Study of Experimental Gene Therapy for Cystinosis

According to a recent press release from the Massachusetts-based biotechnology company Avrobio, Inc., the first patient has been dosed in the Company's phase I/II clinical study of their investigational cystinosis…

Continue Reading First Patient Dosed in Phase I/II Study of Experimental Gene Therapy for Cystinosis